October 20, 2025

IPOPI Launches “Immunity Pulse” – A New Podcast Giving Voice to the PID Community


IPOPI is delighted to announce the launch of its brand-new podcast, Immunity Pulse, now available on Spotify!

Through open and engaging conversations, the podcast gives a voice to patients, caretakers, physicians, and experts to share their experiences and insights about primary immunodeficiencies (PIDs) and associated conditions, highlighting both the scientific and human sides of living with these conditions. Each episode aims to inform, inspire, and raise awareness about critical topics to the global PID community.

The first three episodes are now live:

  • Episode 1SID patients with an underlying PID
    IPPOPI speaks with Dr Silvia Sánchez-Ramón and Mr Vicente Rodrigo to explore PIDs and secondary immunodeficiencies (SIDs), uncovering the connections between them and how an SID might be a sign of a PID.
    To learn more about SIDs, watch IPOPI’s mini-documentary and Hard Talks webinar.
  • Episode 2Whole Lung Lavage Explained
    Kelsea, a patient living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP), shares her personal journey and sheds light on what it’s like to live with this ultra-rare condition and undergo regular Whole Lung Lavage treatments, a unique treatment for this condition and a few PID complications.
    To learn more about aPAP, check out IPOPI’s aPAP leaflet and Hard Talks webinar.
  • Episode 3aPAP Clinical Trial Journey
    Dr Maria Kokosi and Dr Sunita Dhir share their experiences participating in a clinical trial for an ultra-rare disease, offering the perspectives of both physicians and patients. Their discussion provides practical insights and advice for patients living with rare conditions such as PIDs who may need to navigate similar decisions.
    For more information on clinical trial participation, read IPOPI’s leaflet.

Visit the Immunity Pulse page on IPOPI’s webpage to learn more and stay tuned for upcoming episodes!

This podcast was made possible with the support of Octapharma and Savara.